- Home
- MPW vs LGND Comparison
MPW vs LGND Comparison
Compare MPW & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- LGND
- Stock Information
- Founded
- MPW 2003
- LGND 1987
- Country
- MPW United States
- LGND United States
- Employees
- MPW N/A
- LGND 68
- Industry
- MPW Real Estate Investment Trusts
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- LGND Health Care
- Exchange
- MPW Nasdaq
- LGND Nasdaq
- Market Cap
- MPW 2.9B
- LGND 3.2B
- IPO Year
- MPW 2005
- LGND 1992
- Fundamental
- Price
- MPW $4.95
- LGND $204.81
- Analyst Decision
- MPW Hold
- LGND Strong Buy
- Analyst Count
- MPW 6
- LGND 8
- Target Price
- MPW $5.33
- LGND $144.71
- AVG Volume (30 Days)
- MPW 7.3M
- LGND 139.7K
- Earning Date
- MPW 10-30-2025
- LGND 08-05-2025
- Dividend Yield
- MPW 6.57%
- LGND N/A
- EPS Growth
- MPW N/A
- LGND N/A
- EPS
- MPW N/A
- LGND N/A
- Revenue
- MPW $1,419,950,000.00
- LGND $181,488,000.00
- Revenue This Year
- MPW N/A
- LGND $18.41
- Revenue Next Year
- MPW $9.68
- LGND $18.87
- P/E Ratio
- MPW N/A
- LGND N/A
- Revenue Growth
- MPW 114.73
- LGND 53.40
- 52 Week Low
- MPW $3.51
- LGND $81.74
- 52 Week High
- MPW $6.34
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- MPW 44.21
- LGND 74.40
- Support Level
- MPW $4.81
- LGND $183.91
- Resistance Level
- MPW $5.25
- LGND $193.02
- Average True Range (ATR)
- MPW 0.15
- LGND 6.70
- MACD
- MPW -0.04
- LGND 0.32
- Stochastic Oscillator
- MPW 24.44
- LGND 89.12
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.